PRINCIPIA BIOPHARMA | Wantstats

Company ProfileStandardSep 26, 2026

PRINCIPIA BIOPHARMA

Company Profile Analysis

Book Demo Register Your Interest

PRINCIPIA BIOPHARMA - Healthcare showcase

Year Founded & Workforce

2008

57 Employees

Industry

Healthcare

Services

Pemphigus Vulgaris

PRINCIPIA BIOPHARMA Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

PRINCIPIA BIOPHARMA Overview

Company Headquarters: South San Francisco, CA (US)

Founded: 2008

Workforce: ~57

Company Working: Principia Biopharma (Principia) functions as a late-stage biopharmaceutical company focused on developing novel therapies for serious immune mediated diseases. The company offers and develops drugs for the treatment of cancer. The company serves the US market.

Principia Biopharma patented tailored covalency platform allows to develop and design small covalent molecules.

Strategy

Pricipia Biopharma has orphan drug designation for its molecules coupled with strong collaborations to develop drugs through clinical trials. The positive cash flows in the past year has helped the company to continue the drugs for phase 3 clinical trials. If approved, the company has options to gain revenues through commercialization, licensing, and/or royalties for its patented drugs.

Company Snapshot

Employees

2008

Founded

South San Francisco, CA (US)

Headquarters

SWOT Analysis

Strengths

Strong clinical pipeline
Tailored covalency platform for reproducibility
Collaboration for drug development
Positive cash flows

Weaknesses

Major revenue dependence on the upfront payment from collaboration

Opportunities

Utility of available molecules for other indications
Development and commercialization of drugs

Threats

Revenues are subject to clinical trial results

Key Developments

Date	Approach	Development
January 2020	Product Development	Principia announced the expansion of its BTK franchise with PRN473 Topical. Principia believes topical administration will be an important addition to the expected utility of systemic BTK inhibition (rilzabrutinib) and CNS-penetrant BTK therapy (SAR442168/PRN2246).
December 2019	Product Development	Principia updated the PRN1008 Pemphigus clinical program with accelerated enrollment of company’s Phase 3 pivotal trial anticipating results by second half of 2021.

Product Offering

PRINCIPIA BIOPHARMA
- Pemphigus Vulgaris

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →

About the Author

Wantstats Research Team

Wantstats' research desk profiles PRINCIPIA BIOPHARMA as part of our ongoing coverage of the Healthcare sector, drawing on public company data, filings, and market intelligence.

Powering the world's best teams.
From next-gen startups to established enterprises.

See our work in action

Start your data driven journey with us!

Book a Demo Now

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.